Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
NCT02944227
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Wet Macular Degeneration
Interventions
DRUG:
Lucentis
Sponsor
Seoul National University Hospital